GB Sciences Inc

GB Sciences Inc

Our science and research powers discovery. Our engineering and design brings ideas into the real world. GB Sciences marries cutting edge cannabis cultivation and biopharmaceutical research and development.
Biotechnology
1d 5d 1m 6m 1y Max

GB Sciences Inc News

11 Jun

GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-D

GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

28 May

GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropath

OTTAWA, Ontario, May 28, 2019 /PRNewswire/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (GBLX), announced preclinical studies on their proprietary chronic-neuropathic...

14 May

GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility

Positioned to Increase Revenue by Approximately $5.6 Million LAS VEGAS , May 14, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced it is nearing completion of $700,000 in power and water...

16 Apr

GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Canna

Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana,...

02 Apr

Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by D

LAS VEGAS, April 2, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis...

28 Mar

GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients

LAS VEGAS, March 28, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced results from a new study that shows only three chemical varieties of cannabis were sold in the Nevada dispensaries between...

26 Mar

In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility

With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS,...

22 Mar

Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Produ

With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS,...

19 Mar

GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS , March 19, 2019 /PRNewswire/...

12 Mar

GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue

LSU AgCenter issued the following statement on Friday, March 8th. LAS VEGAS , March 12, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that the Louisiana State University Agricultural Center...

Load more

About GB Sciences Inc

To help our patients, GB Sciences is creating a pipeline for the development of novel medicines based on our own patent-pending formulations of chemicals extracted from the Cannabis plant. Through its wholly-owned subsidiary, Growblox Life Sciences, LLC, GB Sciences has now filed three provisional patent applications on new therapies that are complex mixtures of compounds derived from cannabis, and it has licensed an additional approved patent.

GB Sciences partners with universities and contract research organizations (CROs), who bring both expertise and infrastructure at a reasonable cost to our program. Our end goal is not to take these novel formulations to market ourselves, because we know our limitations. Our goal is to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide.

The GB Sciences Scientific Advisory Board provides oversight for product development within GB Sciences’ intellectual property portfolio.

GB Sciences has several advantages over both pharmaceutical companies and academic researchers when it comes to the discovery and validation of new drug formulations from cannabis-derived compounds.

Team

John Poss
Chairman and CEO
Leslie Bocskor
Vice-Chair and Board Member
Dr. Andrea Small-How...
Chief Science Officer
Shane Terry
Board Member
Ksenia Griswold
COO / CFO
John B. Davis
President, GB Sciences Louisiana
Dr. Dominick Monaco
Director of Medical Formulations
Monica Poss
VP of Corporate Planning
Liz Bianco
Director of Publicity
Dr. Helen Turner
VP Innovation, Dean of Natural Sciences & Mathemat...
Dr. Norbert E. Kamin...
Professor, Department of Pharmacology & Toxicology...
Dr. Carlos F. Rios-B...
Corporate Director of Scholarly Inquiry, McLaren H...
Dr. Zoltan Mari
Director of the PD and Movement Disorders Program...
Dr. Alexander Stokes
Assoc. Professor, Univ. of Hawaii-John A Burns Sch...

Participation in events

Jobs

Position
City
Type
Salary
Posted
CITY:
Las Vegas Nevada, United States
TYPE:
Full-Time
SALARY:
$13 - $15 an hour
POSTED:
14 Feb 2019
$ 0.08
4.88%
Open:
0.08
High:
0.09
Low:
0.08
Symbol:
GBLX